What is Sim&cure?
Sim&cure specializes in enhancing patient care for brain aneurysm treatment through a multifactorial approach that prioritizes patient service. The company offers a variety of solutions, such as SimSize, aimed at improving surgical procedures and patient outcomes for healthcare professionals and hospitals. Sim&cure builds partnerships with imaging companies to enhance diagnostic tools and provides tailored therapeutic solutions. Their commitment extends to supporting healthcare systems in optimizing costs while delivering effective treatments, positioning them as a key innovator in medical technology and patient outcomes.
How much funding has Sim&cure raised?
Sim&cure has raised a total of $11.7M across 1 funding round:
Other Financing Round
$11.7M
Other Financing Round (2025): $11.7M with participation from IRDI Capital Investissement, Sofilaro, Elaia Partners, and SWEN Capital Partners
Key Investors in Sim&cure
IRDI Capital Investissement
IRDI Capital Investissement is a seasoned investment partner focused on innovation within SMEs and mid-sized enterprises in the South-West of France, providing equity investment to foster sustainable growth.
Sofilaro
SOFILARO CALEN, a subsidiary of Crédit Agricole, is a regional expert in capital investment, supporting startups, SMEs, and mid-sized enterprises with tailored solutions across various sectors.
Elaia Partners
Elaia Partners is a full-stack investor dedicated to supporting ambitious tech entrepreneurs from inception to leadership, with a strong focus on performance and innovation.
What's next for Sim&cure?
The recent major strategic investment signals a new phase of growth and development for Sim&cure. This capital will likely fuel further research and development into their innovative treatment solutions, expand their market reach, and strengthen partnerships with healthcare providers and imaging companies. The company's focus on optimizing surgical procedures and patient outcomes, combined with strategic financial backing, positions Sim&cure for significant advancements in the competitive neurovascular treatment landscape.
See full Sim&cure company page
